Eric P. Winer

发表

Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support

W. T. Sawyer, C. Lindley, W. Peters, 1999, Psycho-oncology.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

C. Perou, E. Winer, J. Forbes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

PARP Inhibition: “Targeted” Therapy for Triple Negative Breast Cancer

L. Carey, C. Anders, D. Silver, 2010 .

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

E. Rutgers, M. Piccart, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

E. V. Van Allen, B. Overmoyer, E. Mittendorf, 2022, Journal for ImmunoTherapy of Cancer.

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

N. Lin, C. Lascola, Jean J. Zhao, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer

N. Lin, E. Claus, J. Sohl, 2008, Cancer.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

B. Ljung, E. Winer, E. Perez, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Quality‐of‐life research in patients with breast cancer

E. Winer, Eric P. Winer, E. Winer, 1994, Cancer.

Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.

E. Winer, B. Rimer, K. Blackwell, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weight gain in women diagnosed with breast cancer.

E. Winer, B. Rimer, W. Demark-Wahnefried, 1997, Journal of the American Dietetic Association.

Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review

B. Cartmel, T. Sanft, L. Ferrucci, 2023, Frontiers in Oncology.

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

P. Kantoff, E. Winer, M. Conaway, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

D. Berry, G. Parmigiani, J. Schildkraut, 1997, Journal of the National Cancer Institute.

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

E. Winer, C. Shapiro, N. Robert, 2004, Seminars in oncology.

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

R. Gelber, M. Gnant, A. Goldhirsch, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

E. Kohn, E. Winer, W. Barry, 2014, The Lancet. Oncology.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

C. Perou, K. Hoadley, P. Bernard, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 and response to paclitaxel in node-positive breast cancer.

Larry Norton, James N Ingle, Matthew J Ellis, 2007, The New England journal of medicine.

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

S. Loi, G. Hortobagyi, L. Carey, 2022, JAMA oncology.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Eld, M. Piccart, C. Hudis, 2014, Breast.

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

D. Berry, E. Winer, C. Hudis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel administered on a weekly basis for metastatic breast cancer.

J. Manola, E. Winer, L. Parker, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

R. Bast, L. Marks, J. Kurtzberg, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

A. Tutt, M. Piccart, C. Hudis, 2017, Breast.

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors

R. Tamimi, L. Carey, V. Borges, 2023, NPJ breast cancer.

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors

Nikhil Wagle, Todd R. Golub, Huiming Ding, 2017, Nature Communications.

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.

S. Cummings, S. Loader, P. Rowley, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

D. Berry, E. Winer, C. Hudis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Robert B Livingston, Lois Shepherd, James N Ingle, 2010, The Lancet. Oncology.

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

H. Burstein, D. Spigel, N. Tayob, 2023, Breast cancer research and treatment.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

E. Winer, J. Cuzick, A. Tutt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

K Miller, E. Winer, R. Carlson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

J. Griggs, M. Somerfield, C. Hudis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary care for survivors of breast cancer.

E. Winer, H. Burstein, Eric P. Winer, 2000, The New England journal of medicine.

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

E. Winer, J. Gabrilove, C. Cleeland, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

S. Loi, D. Cescon, V. Karantza, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

Donald A. Berry, Eric P. Winer, Larry Norton, 2006 .

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

K. Gelmon, M. Gnant, C. Isaacs, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.

D. Berry, E. Winer, B. Rimer, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and mutational determinants of high tumor mutation burden in breast cancer

O. Cohen, N. Lin, N. Wagle, 2019, bioRxiv.

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

C. Perou, J. Parker, N. Tung, 2023, JAMA oncology.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

M. Ellis, C. Hudis, L. Carey, 2023, The Lancet. Oncology.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

E. Winer, R. Gelman, L. Harris, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

J. Manola, E. Winer, R. Gelman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.

Andrew H. Beck, E. Winer, A. Beck, 2018, Journal of the National Cancer Institute.

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

V. Valero, A. Wolff, H. Burstein, 2022, npj Breast Cancer.

Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.

W. T. Sawyer, E. Winer, C. Lindley, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.

I. Tannock, E. Winer, L. Schwartz, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

E. Winer, J. Bellon, R. Gelman, 2013, Breast Cancer Research and Treatment.

Neratinib Ef ﬁ cacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonampli ﬁ ed Metastatic Breast Cancer

M. Ellis, F. Gao, R. Bose, 2017 .

Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

E. Winer, R. Coombes, A. Buzdar, 2008, Cancer.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Sonali M. Smith, C. Flowers, B. Woda, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

A. Tutt, M. Piccart, C. Hudis, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

R. Gelber, S. Loi, S. Martino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.

C. Vogel, M. O'Rourke, H. Hochster, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

D. Berry, E. Winer, E. Perez, 2006, JAMA.

Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx

G. Hortobagyi, A. Giuliano, S. Shak, 2022, Annals of Surgical Oncology.

Phase II evaluation of thalidomide in patients with metastatic breast cancer.

E. Winer, J. Hanfelt, L. Harris, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

A. Giobbie-Hurder, P. Wen, D. Cahill, 2023, Nature Medicine.

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

E. Winer, H. Burstein, A. Partridge, 2001, Journal of the National Cancer Institute. Monographs.

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

L. Hutchins, C. Vogel, S. Jones, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma

D. Lake, E. Small, N. Vogelzang, 2000, Cancer.

Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)

Minetta C. Liu, L. Carey, J. Leal, 2023, The Journal of Nuclear Medicine.

Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts

E. Mittendorf, T. King, A. Prat, 2023, Cancer.

Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.

E. Winer, B. Rimer, M. Conaway, 1997, The American journal of clinical nutrition.

Why women gain weight with adjuvant chemotherapy for breast cancer.

E. Winer, B. Rimer, W. Demark-Wahnefried, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

E. Winer, H. Burstein, P. Klein, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

E. Winer, M. Cotreau, J. Beckman, 2013, Breast Cancer Research and Treatment.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

E. Winer, J. Baselga, J. Garber, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer

M. Ellis, L. Carey, H. Rugo, 2017 .

Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy

N. Lin, E. Mittendorf, T. King, 2022, Annals of Surgical Oncology.

Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).

E. Winer, A. Sorensen, R. Gelman, 2013 .